187 related articles for article (PubMed ID: 34218498)
21. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment.
Wong GL; Chan HL; Chan HY; Tse PC; Tse YK; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Wong VW
Gastroenterology; 2013 May; 144(5):933-44. PubMed ID: 23415803
[TBL] [Abstract][Full Text] [Related]
22. Comparative Performance of 14 HCC Prediction Models in CHB: A Dynamic Validation at Serial On-Treatment Timepoints.
Wu S; Zhou J; Wu X; Sun Y; Wang B; Kong Y; Zhan S; Jia J; Yang HI; You H
Am J Gastroenterol; 2022 Sep; 117(9):1444-1453. PubMed ID: 35973147
[TBL] [Abstract][Full Text] [Related]
23. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
[TBL] [Abstract][Full Text] [Related]
24. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy.
Jung KS; Kim SU; Song K; Park JY; Kim DY; Ahn SH; Kim BK; Han KH
Hepatology; 2015 Dec; 62(6):1757-66. PubMed ID: 26249025
[TBL] [Abstract][Full Text] [Related]
25. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
[TBL] [Abstract][Full Text] [Related]
26. Reporting and Performance of Hepatocellular Carcinoma Risk Prediction Models: Based on TRIPOD Statement and Meta-Analysis.
Yang L; Wang Q; Cui T; Huang J; Jin H
Can J Gastroenterol Hepatol; 2021; 2021():9996358. PubMed ID: 34513751
[TBL] [Abstract][Full Text] [Related]
27. Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir.
Kim MN; Hwang SG; Rim KS; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kim SU
Liver Int; 2017 Dec; 37(12):1788-1795. PubMed ID: 28418595
[TBL] [Abstract][Full Text] [Related]
28. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B.
Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
JHEP Rep; 2021 Jun; 3(3):100290. PubMed ID: 34041470
[TBL] [Abstract][Full Text] [Related]
29. Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients.
Wu X; Xu X; Zhou J; Sun Y; Ding H; Xie W; Chen G; Ma A; Piao H; Wang B; Chen S; Meng T; Ou X; Yang HI; Jia J; Kong Y; You H
Clin Mol Hepatol; 2023 Jul; 29(3):747-762. PubMed ID: 37165622
[TBL] [Abstract][Full Text] [Related]
30. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
Kim HY; Lampertico P; Nam JY; Lee HC; Kim SU; Sinn DH; Seo YS; Lee HA; Park SY; Lim YS; Jang ES; Yoon EL; Kim HS; Kim SE; Ahn SB; Shim JJ; Jeong SW; Jung YJ; Sohn JH; Cho YK; Jun DW; Dalekos GN; Idilman R; Sypsa V; Berg T; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Janssen HLA; Jang MJ; Lee YB; Kim YJ; Yoon JH; Papatheodoridis GV; Lee JH
J Hepatol; 2022 Feb; 76(2):311-318. PubMed ID: 34606915
[TBL] [Abstract][Full Text] [Related]
31. Verification of hepatitis B-related hepatocellular carcinoma predictive models to evaluate the risk of HCC in patients with liver cirrhosis under antiviral treatment.
Huang X; Wang H; Zhang W; Gu E
Eur J Gastroenterol Hepatol; 2022 May; 34(5):546-552. PubMed ID: 35170528
[TBL] [Abstract][Full Text] [Related]
32. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B.
Wong GL; Chan HL; Wong CK; Leung C; Chan CY; Ho PP; Chung VC; Chan ZC; Tse YK; Chim AM; Lau TK; Wong VW
J Hepatol; 2014 Feb; 60(2):339-45. PubMed ID: 24128413
[TBL] [Abstract][Full Text] [Related]
33. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients.
Lee HW; Ahn SH
World J Gastroenterol; 2016 Oct; 22(37):8314-8321. PubMed ID: 27729738
[TBL] [Abstract][Full Text] [Related]
34. [Risk assessment and management of hepatocellular carcinoma occurrence in patients with chronic hepatitis B in the era of antiviral therapy].
Xin HG; Xie Q
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):297-300. PubMed ID: 33979952
[TBL] [Abstract][Full Text] [Related]
35. The 5-year cumulative incidence of HCC development and treatment regimen in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment.
Wang S; Fang S; Liu Y
J Viral Hepat; 2021 Sep; 28(9):1333-1334. PubMed ID: 34051028
[No Abstract] [Full Text] [Related]
36. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B.
Liang LY; Lee HW; Wong VW; Yip TC; Tse YK; Hui VW; Lui GC; Chan HL; Wong GL
Clin Mol Hepatol; 2021 Jul; 27(3):499-509. PubMed ID: 33631920
[TBL] [Abstract][Full Text] [Related]
37. Utility of Prediction Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues.
Tawada A; Chiba T; Saito T; Ogasawara S; Suzuki E; Ooka Y; Arai M; Kanda T; Shinozaki M; Goto N; Nagashima K; Yokosuka O
Oncology; 2016; 90(4):199-208. PubMed ID: 26934505
[TBL] [Abstract][Full Text] [Related]
38. Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines.
Teng W; Chang TT; Yang HI; Peng CY; Su CW; Su TH; Hu TH; Yu ML; Yang HC; Wu JC
Hepatol Int; 2021 Dec; 15(6):1421-1430. PubMed ID: 34741723
[TBL] [Abstract][Full Text] [Related]
39. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
Hsu YC; Yip TC; Ho HJ; Wong VW; Huang YT; El-Serag HB; Lee TY; Wu MS; Lin JT; Wong GL; Wu CY
J Hepatol; 2018 Aug; 69(2):278-285. PubMed ID: 29551708
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.
Riveiro-Barciela M; Tabernero D; Calleja JL; Lens S; Manzano ML; Rodríguez FG; Crespo J; Piqueras B; Pascasio JM; Comas C; Gutierrez ML; Aguirre A; Suárez E; García-Samaniego J; Rivero M; Acero D; Fernandez-Bermejo M; Moreno D; Sánchez-Pobre P; de Cuenca B; Moreno-Palomares JJ; Esteban R; Buti M
Dig Dis Sci; 2017 Mar; 62(3):784-793. PubMed ID: 28078526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
